JP2025504984A - Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト - Google Patents
Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト Download PDFInfo
- Publication number
- JP2025504984A JP2025504984A JP2024545781A JP2024545781A JP2025504984A JP 2025504984 A JP2025504984 A JP 2025504984A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2025504984 A JP2025504984 A JP 2025504984A
- Authority
- JP
- Japan
- Prior art keywords
- day
- ibudilast
- pharma
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305483P | 2022-02-01 | 2022-02-01 | |
| US63/305,483 | 2022-02-01 | ||
| PCT/US2023/011931 WO2023150093A1 (en) | 2022-02-01 | 2023-01-31 | Ibudilast for use in the treatment of post-covid conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504984A true JP2025504984A (ja) | 2025-02-19 |
| JP2025504984A5 JP2025504984A5 (https=) | 2026-02-03 |
Family
ID=85382992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024545781A Pending JP2025504984A (ja) | 2022-02-01 | 2023-01-31 | Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12171752B2 (https=) |
| EP (1) | EP4472631A1 (https=) |
| JP (1) | JP2025504984A (https=) |
| CN (1) | CN118973574A (https=) |
| CA (1) | CA3251194A1 (https=) |
| WO (1) | WO2023150093A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395747B1 (en) | 1998-08-10 | 2002-05-28 | Sauro Sakoda | Remedies for multiple sclerosis |
| JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ， インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
| US20090197823A1 (en) | 2006-05-09 | 2009-08-06 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
| WO2007142924A1 (en) | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| CA3174413A1 (en) | 2020-04-06 | 2021-10-14 | Yuichi Iwaki | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| GB202005890D0 (en) * | 2020-04-22 | 2020-06-03 | Aivivo Ltd | New uses |
| WO2022181219A1 (ja) | 2021-02-24 | 2022-09-01 | 国立大学法人九州大学 | 新興ウイルス感染症治療薬 |
-
2023
- 2023-01-31 CN CN202380026154.5A patent/CN118973574A/zh active Pending
- 2023-01-31 JP JP2024545781A patent/JP2025504984A/ja active Pending
- 2023-01-31 CA CA3251194A patent/CA3251194A1/en active Pending
- 2023-01-31 US US18/103,983 patent/US12171752B2/en active Active
- 2023-01-31 EP EP23707569.2A patent/EP4472631A1/en active Pending
- 2023-01-31 WO PCT/US2023/011931 patent/WO2023150093A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4472631A1 (en) | 2024-12-11 |
| CN118973574A (zh) | 2024-11-15 |
| WO2023150093A1 (en) | 2023-08-10 |
| US12171752B2 (en) | 2024-12-24 |
| US20230285367A1 (en) | 2023-09-14 |
| CA3251194A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101848712B (zh) | 用异丁地特治疗渐进性神经变性疾病 | |
| US12171752B2 (en) | Methods of treating post-COVID condition(s) | |
| KR20190073365A (ko) | 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제 | |
| JP6177765B2 (ja) | 肺動脈性高血圧症の治療のためのｆｋ５０６の利用 | |
| JP2010506904A (ja) | 精神障害の治療における抗精神病薬およびテトラサイクリンの併用療法 | |
| JP2021512921A (ja) | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン | |
| US20210177812A1 (en) | Methods of suppressing myeloid-derived suppressor cells in patients | |
| JP7652763B2 (ja) | イブジラスト経口製剤およびその使用方法 | |
| US20230090534A1 (en) | Methods of treating glioblastoma multiforme using combination therapy | |
| US12005049B2 (en) | Methods of preventing cancer metastasis | |
| US20220241252A1 (en) | Methods of treating chemical gas exposure | |
| JP7430719B2 (ja) | イブジラストを用いて眼疾患／障害または損傷を治療する方法 | |
| US10946071B2 (en) | Combination of ibudilast and interferon-beta and methods of using same | |
| SK7592002A3 (en) | Method and compositions for treating pulmonary diseases | |
| US12042485B2 (en) | Methods of minimizing cancer metastasis | |
| US20250288561A1 (en) | Nezulcitinib for delivery by nebulized oral inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260126 |